Sep 25, 2026
Standard product labels are built on clinical trial assumptions, rather than real-world patient behavior. That’s why, when a due diligence team needed to assess the true valuation of a pharmaceutical asset, Precision AQ’s Access Consulting and Market Access teams went beyond label-based dosing assumptions to discover how patients actually use the therapy in their day-to-day life and what that means for revenue potential, cost to payer, and long-term value.
What You'll Learn:
- Why label-based dosing assumptions can misrepresent real-world prescription volume and patient lifetime value
- How Precision AQ combined real-world dispensing analysis, persistence curve modeling, and patient-level WAC modeling to compare label-based versus observed dosing behavior
- How translating utilization data into a data-grounded model strengthened investor confidence in acquisition valuation and growth potential